HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial.

Abstract
Bradykinin is the key mediator of symptoms of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of edema of the skin, mucosa and muscle. Icatibant, a bradykinin B(2) receptor antagonist, is an effective and generally well-tolerated treatment option for acute attacks of type I and II HAE. A Phase III randomized, double-blind, placebo-controlled study, FAST-3 (NCT00912093), was designed to further evaluate the efficacy and safety of icatibant in patients presenting with moderate to very severe cutaneous and/or abdominal or mild-to-moderate laryngeal symptoms. Severe laryngeal attacks were treated with open-label icatibant. The controlled phase of FAST-3, completed in October 2010 with results published in December 2011, demonstrated that compared with placebo, icatibant evoked clinically meaningful and statistically significant efficacy across multiple end points in the treatment of type I and II HAE attacks. In addition, icatibant was generally well tolerated and no drug-related serious adverse events were experienced.
AuthorsMurat Baş
JournalExpert review of clinical immunology (Expert Rev Clin Immunol) Vol. 8 Issue 8 Pg. 707-17 (Nov 2012) ISSN: 1744-8409 [Electronic] England
PMID23167682 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • icatibant
  • Bradykinin
Topics
  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects)
  • Bradykinin (administration & dosage, adverse effects, analogs & derivatives)
  • Disease Progression
  • Female
  • Hereditary Angioedema Types I and II (drug therapy)
  • Humans
  • International Cooperation
  • Male
  • Middle Aged
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: